146 related articles for article (PubMed ID: 35485857)
1. FAP-Targeted Radionuclide Therapy of Advanced Radioiodine-Refractory Differentiated Thyroid Cancer With Multiple Cycles of 177 Lu-FAPI-46.
Fu H; Huang J; Sun L; Wu H; Chen H
Clin Nucl Med; 2022 Oct; 47(10):906-907. PubMed ID: 35485857
[TBL] [Abstract][Full Text] [Related]
2. 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT for Detecting Metastatic Lesions in a Case of Radioiodine-Refractory Differentiated Thyroid Cancer.
Fu H; Fu J; Huang J; Pang Y; Chen H
Clin Nucl Med; 2021 Nov; 46(11):940-942. PubMed ID: 34034326
[TBL] [Abstract][Full Text] [Related]
3.
Chen Y; Zheng S; Zhang J; Yao S; Miao W
Ann Nucl Med; 2022 Jul; 36(7):610-622. PubMed ID: 35551610
[TBL] [Abstract][Full Text] [Related]
4.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
5. Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study.
Ballal S; Yadav MP; Moon ES; Roesch F; Kumari S; Agarwal S; Tripathi M; Sahoo RK; Mangu BS; Tupalli A; Bal C
Thyroid; 2022 Jan; 32(1):65-77. PubMed ID: 34641705
[No Abstract] [Full Text] [Related]
6. Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead.
Satapathy S; Bal C
Front Endocrinol (Lausanne); 2022; 13():924841. PubMed ID: 35903277
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of [
Yadav MP; Ballal S; Martin M; Roesch F; Satapathy S; Moon ES; Tripathi M; Gogia A; Bal C
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):805-819. PubMed ID: 37932560
[TBL] [Abstract][Full Text] [Related]
8. Clinical role of 18F-FDG PET/CT for detection of radioactive iodine refractory differentiated thyroid cancer.
Tang X; Shi L; Zhao Z; Wang J; Yang R; Huang Y; Tang J; Chen Z; Wang F
Medicine (Baltimore); 2023 Jun; 102(24):e33878. PubMed ID: 37327310
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
10. 68Ga-FAPI PET/CT in Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy.
Fu H; Fu J; Huang J; Su X; Chen H
Clin Nucl Med; 2021 May; 46(5):427-430. PubMed ID: 33661204
[TBL] [Abstract][Full Text] [Related]
11. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma.
Teunissen JJ; Kwekkeboom DJ; Kooij PP; Bakker WH; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():107S-14S. PubMed ID: 15653659
[TBL] [Abstract][Full Text] [Related]
12. Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy.
Zhao L; Chen J; Pang Y; Fang J; Fu K; Meng L; Zhang X; Guo Z; Wu H; Sun L; Su G; Lin Q; Chen H
Mol Pharm; 2022 Oct; 19(10):3640-3651. PubMed ID: 35917335
[TBL] [Abstract][Full Text] [Related]
13. Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer.
Sakulpisuti C; Charoenphun P; Chamroonrat W
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956886
[TBL] [Abstract][Full Text] [Related]
14. Head-to-Head Comparison of [
Ballal S; Yadav MP; Roesch F; Raju S; Satapathy S; Sheokand P; Moon ES; Martin M; Awarwal S; Tripathi M; Bal C
Thyroid; 2023 Aug; 33(8):974-982. PubMed ID: 37171126
[No Abstract] [Full Text] [Related]
15. PET response assessment in apatinib-treated radioactive iodine-refractory thyroid cancer.
Wang C; Zhang X; Yang X; Li H; Cui R; Guan W; Li X; Zhu Z; Lin Y
Endocr Relat Cancer; 2018 Jun; 25(6):653-663. PubMed ID: 29618578
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Preclinical Evaluation of a Novel FAPI-04 Dimer for Cancer Theranostics.
Zhong X; Guo J; Han X; Wu W; Yang R; Zhang J; Shao G
Mol Pharm; 2023 May; 20(5):2402-2414. PubMed ID: 37015025
[TBL] [Abstract][Full Text] [Related]
17. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
18. Prognostic value of preoperative [
Ding J; Qiu J; Hao Z; Huang H; Liu Q; Liu W; Ren C; Hacker M; Zhang T; Wu W; Huo L; Li X
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1780-1791. PubMed ID: 36695823
[TBL] [Abstract][Full Text] [Related]
19. The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF
de la Fouchardiere C; Alghuzlan A; Bardet S; Borget I; Borson Chazot F; Do Cao C; Godbert Y; Leenhardt L; Zerdoud S; Leboulleux S
Bull Cancer; 2019 Sep; 106(9):812-819. PubMed ID: 31200896
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies.
Privé BM; Boussihmad MA; Timmermans B; van Gemert WA; Peters SMB; Derks YHW; van Lith SAM; Mehra N; Nagarajah J; Heskamp S; Westdorp H
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):1906-1918. PubMed ID: 36813980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
